Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1994-09-02
1995-12-05
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514824, A61K 31135
Patent
active
054729858
ABSTRACT:
TGF-beta activators and TGF-beta production stimulators are employed to prevent or treat conditions characterized by inappropriate proliferation of smooth muscle cells, such as the prevention or reduction of restenosis following angioplasty or other vascular trauma. Such TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation of vascular smooth muscle cells over time. Further provided is a method for upregulating cellular mRNA coding for TGF-beta.
REFERENCES:
patent: 4235988 (1980-11-01), Fildes et al.
patent: 4442119 (1984-04-01), Magarian et al.
patent: 4826672 (1989-05-01), Milius et al.
patent: 4839155 (1989-06-01), McCague
patent: 4859585 (1989-08-01), Sonnenschein et al.
patent: 4879315 (1989-11-01), Magarian et al.
patent: 4962091 (1990-10-01), Eppstein et al.
patent: 4990538 (1991-02-01), Harris et al.
patent: 4997652 (1991-03-01), Wong
patent: 5015666 (1991-05-01), Magarian et al.
patent: 5047431 (1991-09-01), Schickander et al.
patent: 5098903 (1992-03-01), Magarian et al.
patent: 5112305 (1992-05-01), Barath et al.
patent: 5120535 (1992-06-01), Marquardt et al.
patent: 5171217 (1992-12-01), March et al.
patent: 5189046 (1993-02-01), Burch et al.
patent: 5192525 (1993-03-01), Yang et al.
patent: 5242397 (1993-09-01), Barath et al.
Craig et al., "Modern Pharmacology", published 1982 by Little, Brown and Company (Boston), p. 399.
Steele, P. M. et al., "Balloon Angioplasty Natural History of the Pathophysiological Response to Injury in a Pig Model", Circulation Research, vol. 57, No. 1, pp. 105-112, 1985.
Schwartz, R. S. et al., "Restenosis After Balloon Angioplasty, A Practical Proliferative Model in Porcin Coronary Arteries", Circulation, vol. 82, No. 6, pp. 2190-2200, 1990.
Package Insert for Novadex.RTM., (1992).
J. D. Bagdade et al., "Effects of Tamoxifen Treatment on Plasma Lipids and Lipoprotein Lipid Composition", J. Clinical Endocrinology and Metabolism, 70, 1132-1135 (1990).
P. Barath et al., "Low Dose of Antitumor Agents Prevents Smooth Muscle Cell Proliferation After Endothelial Injury", JACC, 13, 252A (Feb. 1989).
G. Bertelli et al., "Adjuvant tamoxifen in primary breast cancer: influence on plasma lipids and antithrombin III levels", Breast Cancer Res. and Treatment, 12, 307-310 (1988).
A. Bruengger et al., "Smooth Muscle Cell of the Canine Prostate in Spontaneous Benign Hyperplasia, Steroid Induced Hyperplasia and Estrogen or Tamoxifen Treated Dogs", The Journal of Urology, 130, 1208-1210 (Dec. 1983).
P. F. Bruning et al., "Tamoxifen, serum lipoproteins and cardiovascular risk", Br. J. Cancer, 58, 497-499 (1988).
A. Butta et al., "Induction of Transforming Growth Factor .beta..sub.1 in Human Breast Cancer in Vivo following Tamoxifen Treatment", Cancer Research, 52, 4261-4264 (Aug. 1, 1992).
H. A. Crissman et al., "Transformed mammalian cells are deficient in kinase-mediated control of progression through the G.sub.1 phase of the cell cycle", PNAS USA, 88, 7580-7584 (Sep. 1991).
P. F. Dimond et al., "TGF-Beta Shows Potential as Therapeutic Agent for Macular Holes", Genetic Engineering News, 7 (Feb. 1, 1993).
M. Y. Farhat et al., "In vitro effect of oestradiol on thymidine uptake in pulmonary vascular smooth muscle cell: role of the endothelium", Br. J. Pharmacol., 107, 679-683 (1992).
G. M. Fischer et al., "A Possible Mechanism in Arterial Wall for Mediation of Sex Difference in Atherosclerosis", Experimental and Molecular Pathology, 43, 288-296 (1985).
J. S. Forrester et al., "A Paradigm for Restenosis Based on Cell Biology: Clues for the Development of New Preventive Therapies", JACC, 17, 758-769 (Mar. 1, 1991).
D. J. Grainger et al., "A large accumulation of non-muscle myosin occurs at first entry into M phase in rat vascular smooth-muscle cells", Biochem. J., 277, 145-151 (1991).
D. J. Grainger et al., "Hexamethylenebisacetamide selectively inhibits the proliferation of human and rat vascular smooth-muscle cells", Biochem. J., 283, 403-408 (1992).
H. Hanke et al., "Inhibition of Cellular Proliferation After Experimental Balloon Angioplasty by Low-Molecular-Weight Heparin", Circulation, 85, 1548-1556 (1992).
J. Hofmann et al., "Enhancement of the Antiproliferative Effect of cis-Diamminedichloroplatinum(II) and Nitrogen Mustard by Inhibitors of Protein Kinase C", Int. J. Cancer, 42, 382-388 (1988).
D. L. Hwang et al., "Effect of Platelet-Contained Growth Factors (PDGf, EGF, IGF-1, and TGF-.beta.) on DNA Synthesis in Porcine Aortic Smooth Muscle Cells in Culture", Experimental Cell Research, 200, 358-360 (1992).
S. S. Jande et al., "Effects of cytochalasin B and dihydrocytochalasin B on calcium transport by intestinal absorptive cells", Chem. Abs., 94, Abstract No. 189223e, p. 385 (1981).
V. C. Jordan, "Long-Term Tamoxifen Therapy to Control or to Prevent Breast Cancer: Laboratory Concept to Clinical Trails" in Hormones, Cell Biology, and Cancer: Perspectives and Potentials; Alan R. Liss, Inc.; pp. 105-123 (1988).
S. M. Jung, "Platelet cytoskeletal protein distributions in two triton-insoluble fractions and how they are affected by stimulants and reagents that modify cytoskeletal protein interactions", Thromb. Res., 50, 775-787 (Jun. 15, 1988)--Abstract Only (Abstract obtained from MEDLINE).
P. R. Kemp et al., "The Id gene is activated by serum but is not required for de-differentiation in rat vascular smooth muscle cells", Biochem. J., 277, 285-288 (1991).
A. Koff et al., "Negative Regulation of G1 in Mammalian Cells: Inhibition of Cycline E-Dependent Kinase by TGF-.beta.", Science, 260, 536-538 (Apr. 23, 1993).
A. M. Lefer et al., "Mediation of Cardioprotection by Transforming Growth Factor-.beta.", Science, 249, 61-64 (6 Jul. 1990).
A. M. Lefer, "Role of transforming growth factor .beta. in cardioprotection of the ischemic-reperfused myocardium" in Growth Factors and Cardiovascular System; P. Cummins, Ed.; Kluwer: London; pp. 249-260 (1993).
H. Y. Lin et al., "Expression Cloning of the TGF-.beta. Type II Receptor, a Functional Transmembrane Serine/Threonine Kinase", Cell, 68, 775-785 (Feb. 21, 1992).
M. W. Liu et al., "Restenosis After Coronary Angioplasty--Potential Biologic Determinants and Role of Intimal Hyperplasia", Circulation, 79, 1374-1387 (Jun. 1989).
R. R. Love et al., "Effects of Tamoxifen on Cardiovascular Risk Factors in Postmenopausal Women", Annals of Internal Medicine, 115, 860-864 (Dec. 1, 1991).
R. R. Love et al., "Effects of Tamoxifen Therapy on Lipid and Lipoprotein Levels in Postmenopausal Patients With Node-Negative Breast Cancer", J. Nat'l Cancer Institute, 82, 1327-1332 (Aug. 15, 1990).
F. J. Manasek et al., "Sensitivity of developing cardiac myofibrils to cytochalasin-B", PNAS USA, 69, 308-312 (1972); Chem. Abs., 76, Abstract No. 149535.
N. A. McCarroll et al., "Preliminary Studies on the Regulation of Secretion of Latent Transforming Growth Factor-.beta. (TGF-.beta.) by Endothelial Cells in Cultures", Clin. Chem., 36, 1152, Abstract No. 0934 (1990).
D. L. McCormick et al., "Retinoid-tamoxifen interaction in mammary cancer chemoprevention", Carcinogenesis, 7, 193-196 (1986).
C. C. McDonald et al., "Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial", BMJ, 303, 435-437 (Aug. 24, 1991).
M. J. Merrilees et al., "Synthesis of TGF-.beta..sub.1 by Vascular Endothelial Cells is Correlated with Cell Spreading", J. Vasc. Res., 29, 376-384 (1992).
S. Nikol et al., "Expression of Transforming Growth Factor-.beta.1 is Increased in Human Vascular Restenosis Lesions", J. Clin. Invest., 90, 1582-1592 (Oct. 1992).
J. Rauterberg et al., "Collagens in Atherosclerotic Vessel Wall Lesions" in Current Topics in Pathology, vol. 87: Vollmer et al., Eds.; Springer-Verlag: Berlin; pp. 163-191 (1993).
R. Ross, "The pathogenesis of atherosclerosis: a perspective for the 1990s", Nature, 362, 801-809 (Apr. 29, 1993).
B. Schoenemanne et al., "
Grainger David J.
Metcalfe James C.
Weissberg Peter L.
Henley III Raymond
NeoRx Corporation
LandOfFree
Prevention and treatment of pathologies associated with abnormal does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention and treatment of pathologies associated with abnormal, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention and treatment of pathologies associated with abnormal will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1374526